NCT07298291Active, not recruiting
Ocular Proteomics Testing In Chronic Atrophy
A Phase 1, Single-Center, Prospective Study to Evaluate the Safety and Clinical Utility of Anterior Chamber Paracentesis for Proteomic Analysis in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
Study to evaluate the safety of routine diagnostic anterior chamber paracentesis (ACP) for proteomic profiling in patients with geographic atrophy (GA)
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 1 Dec 2025
- Start date
- 30 Nov 2025
- Primary completion date
- 30 Jul 2026
- Lead sponsor
- ClinOmicsAI
- Diseases
- Macular degeneration
- NCT number
- NCT07298291
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 30 Nov 2025 to the primary completion date, 30 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of systemic anticoagulation therapy that cannot be safely discontinued prior to ACP.
Other illness
- Presence of active ocular infection or inflammation in either eye at the time of screening.
- History of intraocular surgery in the study eye within the three months preceding enrollment.
- Known hypersensitivity or contraindication to any of the medications or procedures used in the study.
Other
- Intraocular pressure (IOP) greater than 21 mmHg in the study eye at screening
- Pregnant or nursing women.
Who the study is looking for
- Male or female subjects aged between 50 and 89 years, inclusive
- For the GA cohort: Clinical diagnosis of GA secondary to AMD or dAMD in the study eye, confirmed by fundus autofluorescence imaging and spectral-domain optical coherence tomography (SD-OCT).
- For the control cohort: No clinical evidence of retinal disease in either eye.
- Best-corrected visual acuity (BCVA) of ≥20/200 in the study eye, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts
- Ability and willingness to provide written informed consent before any study-specific procedures.
Age in the registry: 50 years to 89 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erie Retina Research Coordinator of this site? Confirm its status | Erie | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.